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Regarding these facts, the recently issued guidelines from the
RECIST working group is of major importance to standardize the
i-RECIST. These guidelines (i) define the concept of “unconfirmed
PD ‘/’ confirmed PD” according to the results of the imaging per-
formed after the initial PD, (ii) include clinical stability in the defi-
nition, and (iii) define confirmed PD when a new lesion occurs
[5]. The authors should be applauded for this initiative; the defini-
tion of endpoints do not differ according to the sponsor.
Use of a common and standardized language is critical when
designing and analyzing clinical trials. Current ongoing trials used
widely different definitions of confirmed PD, creating major difficul-
ties when discussing results. The RECIST working group guidelines
should be endorsed to avoid non-reproducibility of trial results.
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Cancer immunotherapy trial registrations
increase exponentially but chronic
immunosuppressive glucocorticoid therapy
may compromise outcomes
T cell checkpoint-targeted immunotherapy is effective in multi-
ple cancers, but only in subsets of patients [1]. Failure of immu-
notherapy may be secondary to tumour intrinsic and/or systemic
factors that impair immune response. Glucocorticoid adminis-
tration has known systemic immunosuppressive effects [2] with
potential to impair immunotherapy outcome [3], and should
therefore be regulated at patient enrolment.
We performed a cross-sectional analysis of T cell checkpoint-
targeted cancer immunotherapy trials in solid malignancies regis-
tered on the U.S. National Institutes of Health (NIH) trial registry
(clinicaltrials.gov) by October 7, 2016. Trials were searched by
study type, condition, and interventions targeting the T cell check-
point proteins CTLA-4, PD-1, PD-L1, PD-L2, LAG3, B7-H3,
CD137, OX40, CD27 and GITR. Trials were reviewed manually
and independently by two clinicians and registered data on gluco-
corticoid administration within enrolment criteria recorded.
We identified 1017 registered T cell checkpoint-targeted cancer
immunotherapy trials. The number of registrations has progres-
sively increased, exponentially between 2010 and 2015 (R2 ¼ 0.95)
(Figure 1A). For the completed years, 2001–2015, chronic gluco-
corticoid administration was stated as an exclusion criterion in
40% (276/685), permitted in 29% (201/685) and not specified in
30% (208/685) of trial registration details. The proportion of trials
that did not allow glucocorticoid use has decreased significantly
(P< 0.001), while the proportion allowing glucocorticoid use has
increased significantly (P< 0.001) (Figure 1B). Of the trials per-
mitting glucocorticoid use, the maximum permitted dose of pre-
dnisolone equivalent per day was up to 10 mg in 57% of trials
(115/201), over 10 mg in 4% of trials (9/201) and not specified in
14% of trials (28/201); 24% of trials (49/201) permitted chronic
glucocorticoid use for physiological replacement.
These findings are concerning. The immunosuppressive effects
of glucocorticoids are dose dependent, starting at less than 10 mg
of prednisolone per day [2], and may be compounded by hypoal-
buminaemia present in patients with cancer [4]. Moreover, our
pre-clinical work has demonstrated that low dose glucocorticoid
administration is sufficient to suppress response to cancer immu-
notherapy [3]. Therefore, unregulated glucocorticoid adminis-
tration may result in treatment failure independent of the T cell
checkpoint-targeted agent or tumour type.
The use of glucocorticoids as appetite stimulants and anti-
emetics, particularly relevant in combination trials with emeto-
genic chemotherapy or radiotherapy, may also be immunosup-
pressive and will require critical review. While the use of
glucocorticoids for adrenal replacement or chronic immune ill-
ness may be unavoidable, stratification for their use at enrolment
should be considered.
In addition to glucocorticoid administration, endogenous glu-
cocorticoid levels may also impact on response to immunother-
apy. Monitoring and stratification according to baseline
glucocorticoid levels, or clinical surrogates of these such as longi-
tudinal weight measurements [3], may yield predictive and prog-
nostic markers of response.
We note that the chronic use of glucocorticoids should be con-
sidered independently from the use of glucocorticoids in manag-
ing immune-related adverse events during immunotherapy. In
Letters to the editor Annals of Oncology
VC The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and
reproduction in any medium, provided the original work is properly cited.
fact, the positive correlation of autoimmune side effects and
treatment efficacy [5] provides further rationale for considering
the role of systemic immunomodulatory variables in determining
response to immunotherapy.
Our study is limited by the exclusive use of data from the U.S.
NIH trial registry. However, this is the largest clinical trial regis-
try, and the registration of key inclusion and exclusion criteria is
international standard [6] and has been mandatory for consider-
ation of publication by the International Committee of Medical
Journal Editors member journals since 2005.
In summary, we find glucocorticoid administration to be a
neglected immunomodulatory variable in cancer immunother-
apy trials, and suggest striving for greater harmony in the moni-
toring and regulation of systemic glucocorticoids to improve
outcomes in cancer immunotherapy.
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Figure 1. Longitudinal registration count and glucocorticoid administration in T cell checkpoint-targeted cancer immunotherapy trials. (A) Annual registration count of T cell checkpoint-tar-
geted cancer immunotherapy trials. Trials registered by October 7, 2016 on the U.S. National Institutes of Health (NIH) trial registry were categorized according to year of registration and check-
point protein target. T cell checkpoint proteins targeted in fewer than 10 trials are grouped as ‘other’, and include single agent OX40, GITR, CD137, B7-H3, LAG3, PD-L2, CD27 and trials
comparing multiple checkpoint-targeting agents. ‘Combination’ trials include all pre-deﬁned T cell checkpoint-targeted agents used in combination with another agent. (B) Speciﬁcation of glu-
cocorticoid administration within enrolment criteria of T cell checkpoint-targeted cancer immunotherapy trials. Trials registered on the U.S. NIH trial registry between 2001 and 2015 were cate-
gorized according to the speciﬁcation of chronic systemic glucocorticoid administration within registered patient enrolment criteria. Univariate analysis for data presented was performed using
the Cochran–Armitage test for trend assuming monotonical change over time and expected frequencies were met (80% of expected frequencies>5). ***P< 0.001; NS¼ not signiﬁcant.
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